Avadel and Jazz Pharmaceuticals Settle $90 Million Narcolepsy Drug Dispute Over Lumryz
核心洞察
Avadel Pharmaceuticals and Jazz Pharmaceuticals reached a global settlement ending years of patent and antitrust litigation, with Jazz paying Avadel $90 million and granting perpetual patent licenses for Lumryz.
The agreement provides Avadel with a clear pathway to expand Lumryz into idiopathic hypersomnia (搜索) treatment beginning March 1, 2028, subject to FDA approval.
Under the settlement terms, Avadel will pay Jazz ongoing royalties of 3.85% for narcolepsy (搜索) sales through 2036, and 10% for future approved indications.
Avadel Pharmaceuticals and Jazz Pharmaceuticals have reached a comprehensive $90 million settlement that resolves years of patent and antitrust litigation surrounding Lumryz, the first and only once-nightly treatment for narcolepsy (搜索). The agreement, announced October 22, 2025, provides Avadel with long-term intellectual property clarity and establishes a defined commercial pathway for expanding Lumryz into additional sleep disorders.
Settlement Terms and Financial Impact
Under the primary settlement terms, Jazz will pay Avadel $90 million and waive its right to receive royalties on past Lumryz sales through September 30, 2025. Jazz has also granted Avadel a perpetual, worldwide license to any patents that could be asserted against Lumryz for present and future indications, strengths, conditions of use, dosages, and presentations.
The companies will promptly file stipulations to dismiss patent and antitrust cases in the US District Court for the District of Delaware. The settlement resolves all remaining claims between the companies, including Avadel's antitrust and contract allegations that had been scheduled for a November jury trial.
Royalty Structure and Commercial Rights
Beginning October 1, 2025, Avadel will pay Jazz ongoing royalties of 3.85% of net Lumryz sales in narcolepsy (搜索) through February 18, 2036, with potential reduction to 3.75%. For any future FDA-approved indications, Lumryz will be subject to a 10% royalty rate (potentially reducible to 9.5%) of net sales until February 18, 2036.
In exchange, Avadel has granted Jazz a perpetual worldwide, royalty-free covenant not to sue regarding Avadel's patents in connection with Jazz's Xywav and Xyrem products for any present and future indications.
Pathway to Idiopathic Hypersomnia
The settlement establishes a clear timeline for Lumryz expansion into idiopathic hypersomnia (搜索), with sales permitted beginning no earlier than March 1, 2028, pending FDA approval. Jazz has agreed not to challenge the approvability of Lumryz for any present and future indications, including idiopathic hypersomnia.
Lumryz Clinical Profile and Approvals
Lumryz (sodium oxybate) for extended-release oral suspension received FDA approval on May 1, 2023, as the first and only once-at-bedtime treatment for cataplexy (搜索) or excessive daytime sleepiness (搜索) in adults with narcolepsy (搜索). The FDA expanded approval on October 16, 2024, to include pediatric patients seven years of age and older with narcolepsy.
The FDA approval was supported by results from REST-ON, a randomized, double-blind, placebo-controlled, pivotal Phase 3 trial in adults with narcolepsy (搜索). Lumryz demonstrated statistically significant and clinically meaningful improvements in three co-primary endpoints: excessive daytime sleepiness (搜索) measured by the Maintenance of Wakefulness Test, clinicians' overall assessment of patients' functioning using the Clinical Global Impression-Improvement scale, and cataplexy (搜索) attacks, across all three evaluated doses compared to placebo.
Orphan Drug Exclusivity and Clinical Superiority
The FDA granted seven years of Orphan Drug Exclusivity to Lumryz for treating cataplexy (搜索) or excessive daytime sleepiness (搜索) in both adult and pediatric narcolepsy (搜索) patients due to a finding of clinical superiority over currently available oxybate treatments. The FDA determined that Lumryz makes a major contribution to patient care by providing a once-nightly dosing regimen that avoids nocturnal arousal required for twice-nightly oxybate products.
Safety Profile and Regulatory Framework
Lumryz carries a boxed warning regarding the risk of taking the medication with other central nervous system depressants, which may cause serious medical problems including respiratory depression, hypotension, drowsiness, syncope, and death. The active ingredient, sodium oxybate, is a form of gamma hydroxybutyrate (GHB), a controlled substance available only through certified pharmacies in the Lumryz REMS program.
The most common side effects in adults include nausea, dizziness, bedwetting, headache, and vomiting. In pediatric patients, the most common side effects include nausea, bedwetting, vomiting, headache, decreased weight, decreased appetite, dizziness, and sleepwalking.